This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Moderna ETFs to Gain on Positive 'Real-World' Study Data
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.
Novavax ETFs to Shine Bright on Positive Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development and distribution amid the pandemic.
ETFs to Tap Amgen's Drive for Cancer Deal
by Sweta Killa
Amgen (AMGN) has agreed to buy Five Prime Therapeutics (FPRX) for $1.9 billion.
5 ETF Investing Areas for March to Boost Returns
by Sweta Jaiswal, FRM
Here we discuss a few ETFs that can enrich investors' portfolio in March amid a strong wave of optimism surrounding the coronavirus vaccine and introduction of another round of fiscal stimulus.
How Will Biotech ETFs React to Q4 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?
by Sweta Jaiswal, FRM
Positive coronavirus vaccine update from Moderna (MRNA) has hogged investors' attention.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
ETF Areas Thriving During Coronavirus Pandemic
by Sweta Jaiswal, FRM
We highlight some ETF areas that held their ground and gained popularity among investors amid the coronavirus crisis.
Wil Nasdaq ETFs Win in 2021 After the Best Year Since 2009?
by Sanghamitra Saha
The Nasdaq clocked double-digit gains for two years in a row in 2020. It may log double-digit gains in 2021 all over again if the virus scenario does not improve as fast as expected.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Get Your Portfolio Christmas-Ready With These ETFs
by Sweta Jaiswal, FRM
Here we highlight some ETFs that can help investors make the most of the favorable investing opportunities amid the coronavirus crisis.
Moderna Vaccine: The Power of mRNA Technology
by Kevin Cook
Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine
ETF Sectors to Bet on Positive Vaccine News
by Sweta Jaiswal, FRM
The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.
Moderna ETFs to Shine on Vaccine News as Outbreak Worsens
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Here's Why Healthcare ETFs Are Rallying Post Elections
by Sweta Jaiswal, FRM
Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.
How Will Biotech ETFs React to These Q3 Earnings Release?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain
by Sweta Jaiswal, FRM
Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.
Biotech ETFs to Shine on Coronavirus Antibodies Progress
by Sweta Jaiswal, FRM
With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.
5 ETFs That Make Attractive Investment Choices in Q4
by Sweta Jaiswal, FRM
Here we discuss ETFs that can be a good addition for enhanced portfolio returns in the fourth quarter of 2020.
Biotech ETFs to Gain on Trump's COVID-19 Treatment Protocol
by Sweta Jaiswal, FRM
The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.
Top-Performing Biotech ETFs Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.